ALGORAE PHAR SP.ADR/10

Depository Receipt · US53838R1077 · A0YGYX (OTCQ)

No Price

n/a

Company Profile for ALGORAE PHAR SP.ADR/10 Depository Receipt

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Sydney, Australia.

Get up to date insights from finAgent about ALGORAE PHAR SP.ADR/10

Company Data

Name ALGORAE PHAR SP.ADR/10

Company Living Cell Technologies Limited

Website https://www.lctglobal.com

Primary Exchange

Frankfurt

WKN A0YGYX

ISIN US53838R1077

Asset Class Depository Receipt

Sector Healthcare

Industry Biotechnology

CEO David Richard Hainsworth

Market Capitalization 11 Mio

Country Australia

Currency EUR

Employees 0,0 T

Address Tower 2, 2000 Sydney

IPO Date 2008-01-30

Ticker Symbols

Name	Symbol
Over The Counter	LVCLY
Frankfurt	LHI1.F

More Shares

Investors who hold ALGORAE PHAR SP.ADR/10 also have the following shares in their portfolio:

HALOZYME THERAPEUTICSCS INC Share

SG ISSUER NTS 11/02/30 Bond

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog